Actionable news
0
All posts from Actionable news
Actionable news in CYNO: Cynosure, Inc.,

Cynosure: And Chief Financial Officer Sharon Merrill Associates Cynosure, Inc.

The following excerpt is from the company's SEC filing.

(617) 542-5300

(978) 256-4200

CYNO@investorrelations.com

tbaker@cynosure.com

Cynosure Announces Record First-Quarter 2016 Results;

Revenues Increase 26% from Prior Year to $94.7 Million

First-Quarter 2016 Highlights:

North America product revenue of $55.2 million, up 76 percent year-over-year

Non-GAAP earnings of $0.19 per diluted share; GAAP earnings of $0.12 per diluted share

Non-GAAP margin up 90 bps to 60.1%; GAAP gross margin improves 140 bps to 58.5%

Full U.S. rollout of SculpSure

platform for non-invasive fat reduction helps pace strong double-digit revenue growth in North America

Cash and investments of $178.2 million at March 31, 2016

Westford, MA April 26, 2016

Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended March 31, 2016.

Sustained momentum in North America, in part reflecting the full U.S. launch of SculpSure, helped generate solid first-quarter results for Cynosure, as our domestic business posted year-over-year top-line growth for the 22

consecutive quarter, said Chief Executive Officer Michael Davin. Higher revenue and favorable product mix drove increased margins and profitability, even as we accelerated our sales and marketing investments during the quarter to coincide with the rollout of SculpSure across all of our U.S. direct sales territories. We are extremely pleased with the progress of the launch and the response SculpSure is receiving from physicians and patients.

Product revenue from North America increased 76 percent from the first quarter of 2015 to $55.2 million, representing 72 percent of our total product revenue for the quarter, Davin said. International product revenue was down 13 percent year-over-year including the impact of foreign exchange and down 11 percent on a constant currency basis, reflecting ongoing economic weakness in the EMEA region. The softness among our European direct subsidiaries and international third-party distributors was partly offset by our subsidiaries results in the Asia Pacific region, where we posted 17 percent higher product revenue on a constant currency basis for the quarter as compared to last year.

First Quarter 2016 Financial Results

Revenue was $94.7 million for the first quarter of 2016, an increase of 26 percent from the prior-year period. Product revenue in North America grew 76 percent year-over-year to $55.2 million. International product revenue was $21.9 million, or $22.5 million adjusted for constant currency. Parts, service and disposables revenue increased 26 percent year-over-year to $16.9 million. Royalty revenue decreased $4.3 million to $0.7 million reflecting the final $3 million payment received in the first quarter of 2015 under a previously disclosed settlement agreement with Tria Beauty.

Gross margin for the first quarter of 2016 was 58.5 percent, compared with 57.1 percent for the same period in 2015. On a non-GAAP basis, excluding non-cash charges related to the amortization of intangibles, gross margin for the first quarter of 2016 increased to $56.9 million, or 60.1 percent of revenue, compared with $44.3 million, or 59.2 percent of revenue, in the prior-year period. Gross margin for the 2015 period was affected by the $3 million final payment from Tria Beauty.

Total operating expenses for the first quarter of 2016 increased 25 percent to $51.0 million from $40.7 million in the same period in 2015, partly reflecting the SculpSure launch. Sales and marketing expenses for the first quarter of 2016 were $35.6 million, or 37.6 percent of total revenue, compared with sales and marketing expenses of $25.7 million, or 34.3 percent of total revenue, for the first quarter of 2015. The increase reflects the addition of sales, clinical support and marketing personnel, as well as additional marketing investments associated with the SculpSure launch.

Operating income for the first quarter of 2016 increased to $4.5 million from $2.1 million in the prior-year period. On a non-GAAP basis, excluding acquisition costs and amortization of intangibles, income from operations for the first quarter of 2016 was $6.6 million, compared with $5.1 million for the prior-year period.

Net income for the first quarter of 2016 was $2.8 million, or $0.12 per diluted share, compared with break-even net income, or $0.00 per diluted share, for the prior-year period. GAAP earnings included a $0.7 million unrealized gain on foreign currency in the 2016 period and a $1.7 million

unrealized loss on foreign currency in the 2015 period. On a non-GAAP basis, excluding acquisition costs, non-cash unrealized foreign exchange measurement gains and losses, and amortization of intangibles, net income for the first quarter of 2016 was $4.3 million, or $0.19 per diluted share, compared with $3.3 million, or $0.15 per diluted share, for the prior-year period.

Cash and investments at March 31, 2016 were $178.2 million, compared with $182.8 million at year-end 2015.

Recent Highlights

Cynosures technology was the subject of 20 scientific presentations at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The 17 oral abstracts and three ePosters presented at ASLMS detailed data from research programs for a range of indications addressed by the Companys energy-based technologies, including non-invasive fat reduction, skin rejuvenation, melasma, facial photoaging, tattoo removal and genitourinary syndrome of menopause.

Cynosure entered into an expanded distribution agreement with El.En. S.p.A. under which the Company will market and distribute MonaLisa Touch for gynecologic health indications in Germany, Spain and the United Kingdom. Cynosure is currently marketing MonaLisa Touch in North America under an exclusive distribution agreement signed with El.En. in late 2014.

Business Outlook

The global trend toward less invasive aesthetic procedures plays directly into the strength of our products, technology platforms and worldwide distribution network, Davin said. We have a number of exciting catalysts in the quarters ahead, and we will apply the same financial and operational discipline as we execute our growth strategy going forward.

First-Quarter 2016 Financial Results Conference Call

In conjunction with the announcement of its first-quarter financial results, Cynosure will host a conference call for investors and analysts at 9:00 a.m. ET today. On the call, Michael Davin and Timothy Baker, the Companys President, Chief Operating Officer and Chief Financial Officer, will discuss Cynosures financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the Investors section of the Companys website at www.cynosure.com. The live call can also be accessed by dialing (877) 709-8155 or (201) 689-8881. If you are unable to listen to the live call, the webcast will be archived for one year on the Companys website.

About Cynosure, Inc.

Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through non-invasive and minimally invasive laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecological health. Cynosure also markets radiofrequency energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosures product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries. For corporate or product information, visit Cynosures website at www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including Cynosures expectations with respect to timing and success of product launches, regulatory clearances and international registrations, as well as other statements containing the words, believes, looks forward, anticipates, plans, expects, will and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the market price of Cynosures stock prevailing from time to time, the nature of other investment opportunities presented to the Company from time to time, the Companys cash flow from operations, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosures ability to develop and commercialize new products, including the MonaLisa Touch and SculpSure products, Cynosures reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosures most recent Annual Report on Form 10-K for the year ended December 31, 2015, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosures views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

These forward-looking statements should not be relied upon as representing Cynosures views as of any date subsequent to the date of this press release.

Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

Three Months Ended March 31,

94,664

74,912

Cost of revenues

39,244

32,139

Gross profit

55,420

42,773

Operating expenses

Selling and marketing

35,591

25,696

Research and development

Amortization of intangible assets acquired

General and administrative

50,969

40,720

Income from operations

Interest expense, net

Other income (expense), net

(1,663

Income (loss) before income taxes

Income tax provision (benefit)

Net income (loss)

Diluted net income (loss) per share

Diluted weighted average shares outstanding

23,154

21,664

Basic net income (loss) per share

Basic weighted average shares outstanding

22,736

Condensed Consolidated Balance Sheet

(In thousands)

Assets:

Cash, cash equivalents and marketable securities

93,464

108,587

Short-term investments and related financial instruments

46,469

35,412

Accounts receivable, net

38,517

42,012

Inventories

85,648

79,768

Prepaid expenses and other current assets

16,084

21,356

Total current assets

280,182

287,135

Property and equipment, net

43,220

39,706

Long-term marketable securities

38,226

38,761

Goodwill and intangibles, net

148,003

150,124

Deferred tax asset, noncurrent

18,261

17,882

Other noncurrent assets

Total assets

528,917

534,610

Liabilities and stockholders equity:

Accounts payable and accrued expenses

67,505

79,501

Deferred revenue

24,012

24,803

Capital lease obligations

Total current liabilities

92,421

105,045

Capital lease obligations, net of current portion

17,369

17,372

Deferred revenue, net of current portion

Other long-term liabilities

Total stockholders equity

411,629

404,402

Total liabilities and stockholders equity

To supplement our consolidated financial statements presented in accordance with GAAP, Cynosure uses non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted net income per share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The non-GAAP financial measures included in this press release exclude costs associated with the acquisitions and amortization of intangible assets acquired, as well as unrealized foreign exchange gains or losses for the three months ended March 31, 2016 and 2015. This exclusion may be different from, and therefore not comparable to, similar measures used by other companies.

Cynosures management believes that the non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding the acquisition-related costs, amortization and foreign exchange costs that may not be indicative of our core business operating results. Cynosure believes that both management and investors benefit from referring to the non-GAAP financial measures in assessing Cynosures performance and when planning, forecasting and analyzing future periods. The non-GAAP financial measures also facilitate managements internal comparisons to Cynosures historical performance and our competitors operating results. Cynosure believes that the non-GAAP measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in our financial and operational decision making.

Reconciliation of GAAP Income Statement Measures to Non-GAAP Income Statement Measures (Unaudited)

Non-GAAP adjustments to gross profit:

Costs associated with amortization

Total Non-GAAP adjustments to gross profit

Non-GAAP Gross profit dollars

56,882

44,327

Non-GAAP Gross profit percentage

Non-GAAP adjustments to income from operations:

Costs associated with acquisitions and amortization

Total Non-GAAP adjustments to income from operations

Non-GAAP Income from operations

Three Months Ended March 31,

Non-GAAP adjustments to net income (loss):

Unrealized foreign exchange (gain) loss

Income tax effect of non-GAAP adjustments

(1,417

Total Non-GAAP adjustments to net income (loss)

Non-GAAP net income

Income tax effect of Non-GAAP adjustments

Non-GAAP diluted net income per share

Weighted average shares used to compute GAAP diluted net income (loss) per share

Weighted average shares used to compute Non-GAAP diluted net income per share

22,123

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Cynosure makes a similar move, sign up!

Other recent filings from the company include the following:

Cynosure's President and CFO just cashed-in 14,008 options - April 19, 2016
Cynosure's Chairman and CEO just cashed-in 74,729 options - April 19, 2016
Executive VP of Cynosure just cashed-in 15,890 options - April 19, 2016
Cynosure's Chairman and CEO just cashed-in 61,377 options - April 18, 2016